BAT-4406F

达尔扑拜单抗

Report date: 2026/03/31 20:00:21

Base Information

Drug NameBAT-4406F

Drug Alias NameBAT-4406BAT-4406F

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsGlomerulosclerosis, Focal SegmentalNeuromyelitis Optica

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaNDA/BLA

Originator CompaniesBio-Thera Solutions Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBio-Thera Solutions Ltd

Inactive CompaniesN/A

Active IndicationsGlomerulosclerosis, Focal SegmentalNeuromyelitis Optica

Inactive IndicationsN/A

Other Information

ATC CodeN/A